Catatonia is a severe disorder affecting how the brain controls movement and communication, but with proper recognition and treatment, most people can recover. Though once thought to only happen in schizophrenia, catatonia can emerge in various mental health conditions and even physical illnesses, making it more common than many realize.

When the Brain’s Movement System Stops Working: Understanding Catatonia Treatment

Treating catatonia focuses on quickly restoring a person’s ability to move, speak, and interact with the world around them. The primary goal is to reverse the abnormal brain signals that freeze or disrupt motor function, while also addressing any underlying conditions that might have triggered the episode. Treatment becomes urgent because catatonia can affect essential functions like eating and drinking, and in severe cases, can become life-threatening if left untreated.^[1]

The approach to treating catatonia depends on several factors, including how severe the symptoms are, whether the person can eat and maintain basic body functions, and what underlying condition might be causing the problem. Someone who refuses to eat or drink requires immediate intervention, while milder cases may allow for a more measured approach. Understanding that catatonia exists on a spectrum rather than as a simple yes-or-no condition helps doctors tailor their response to each person’s specific situation.^[7]

Medical professionals recognize that prompt treatment during the early phases of catatonia is crucial for achieving lasting improvement. Standard treatments approved by medical societies have proven effective for many years, though researchers continue to explore new approaches through clinical trials. The good news is that despite how severe catatonia can appear, it generally has a positive outlook when treated appropriately.^[10]

Standard Treatment Approaches

Benzodiazepines, particularly a medication called lorazepam, serve as the first-line treatment for catatonia in most cases. These medications work by enhancing the activity of a brain chemical called GABA, which helps calm overactive neural circuits. When someone with catatonia receives lorazepam, doctors often see improvement within hours or days. The medication essentially “resets” the brain’s movement control systems that have become stuck.^[10]

Doctors typically start with a test dose of lorazepam to confirm the diagnosis and see if the person responds. If the first dose produces noticeable improvement in movement or communication, this confirms both the diagnosis and that benzodiazepines will likely work. Treatment then continues with regular doses throughout the day. Some people need only a few days of treatment, while others might require several weeks depending on how long the catatonia has persisted and what caused it.^[12]

The medication can be given by mouth if the person is able to swallow, or through an intravenous line if they cannot. Doses vary from person to person, but doctors carefully monitor the response and adjust accordingly. While lorazepam is generally safe, it can cause drowsiness, confusion, or breathing problems at higher doses, so medical supervision remains essential throughout treatment.^[12]

Other benzodiazepines like clonazepam and midazolam have also shown success in treating catatonia, though lorazepam remains the most studied and commonly used option. The choice between medications may depend on availability, the person’s other health conditions, and how they respond to initial treatment.^[12]

When Medications Don’t Work: Electroconvulsive Therapy

Electroconvulsive therapy, commonly known as ECT, stands as the most effective treatment for catatonia, especially when benzodiazepines fail to produce improvement. During ECT, doctors deliver carefully controlled electrical currents to the brain while the person is under anesthesia. This triggers a brief seizure that somehow resets the brain’s neural circuits, often producing dramatic improvements in catatonic symptoms.^[10]

Research shows that ECT helps about 80 to 100 percent of people with catatonia, making it remarkably effective even in severe cases. The treatment works faster than medications alone, with many people showing significant improvement after just a few sessions. A typical course might involve treatments three times per week for several weeks, though some people improve after just one or two sessions.^[10]

ECT is particularly valuable for malignant catatonia, the most dangerous form where the person develops fever and unstable vital signs. In these life-threatening situations, ECT can be life-saving when medications haven’t worked quickly enough. Some people who recover from catatonia may need maintenance ECT sessions on an outpatient basis to prevent the symptoms from returning.^[12]

Modern ECT is much safer than historical procedures, with anesthesia preventing any pain and muscle relaxants preventing physical convulsions. The main side effects involve temporary memory problems and confusion immediately after treatment, which typically resolve within a few hours or days.^[10]

Alternative Medication Approaches

When benzodiazepines and ECT are unavailable or inappropriate, doctors may try other medications. Zolpidem, a sleeping medication, has shown promise in some cases of catatonia. It works similarly to benzodiazepines by affecting GABA receptors in the brain, though through a slightly different mechanism. Some people who don’t respond to lorazepam show improvement with zolpidem.^[12]

Amantadine, a medication originally developed to treat Parkinson’s disease and flu infections, can help some people with catatonia. It works by increasing dopamine activity in the brain, which may help restore normal movement control. Doctors sometimes try amantadine after benzodiazepines fail but before moving to ECT.^[13]

Carbamazepine, typically used as a mood stabilizer and seizure medication, has helped some individuals with catatonia. The exact reason it works remains unclear, but it may stabilize the neural circuits involved in movement control. Similarly, bromocriptine, another dopamine-boosting medication, has shown benefits in certain cases.^[12]

For malignant catatonia with fever and severe rigidity, dantrolene may be added to treatment. This muscle relaxant helps reduce muscle stiffness and can lower body temperature, addressing some of the most dangerous aspects of severe catatonia. It’s particularly useful when catatonia resembles neuroleptic malignant syndrome, a similar condition triggered by antipsychotic medications.^[12]

Duration and Follow-Up Care

The length of treatment varies widely depending on the person and the underlying cause of their catatonia. Some people respond within days and may only need medication for a few weeks. Others might require months of treatment, especially if catatonia accompanies a chronic mental health condition like bipolar disorder or depression. Treatment for the underlying psychiatric or medical condition must continue even after catatonic symptoms resolve.^[14]

Regular follow-up appointments help doctors monitor for any return of catatonic symptoms. Because catatonia can recur, especially in people with mood disorders, ongoing vigilance remains important. Some individuals develop a pattern of recurring episodes, requiring long-term preventive strategies including maintenance medications or periodic ECT sessions.^[12]

During recovery, people need support with basic activities of daily living. Physical therapy may help restore strength and coordination after prolonged immobility. Occupational therapy assists with regaining independence in self-care tasks. Mental health counseling addresses the psychological impact of experiencing such a frightening condition.^[3]

Emerging Treatments in Clinical Research

While standard treatments work for most people with catatonia, researchers continue exploring new approaches through clinical trials. These studies investigate medications that work through different brain pathways, potentially offering options for people who don’t respond to current treatments or who cannot tolerate benzodiazepines and ECT.^[5]

NMDA Receptor Modulators

Scientists studying catatonia have discovered that excessive activity at brain receptors called NMDA receptors may contribute to the condition. These receptors respond to a chemical messenger called glutamate, which helps regulate brain activity. When these receptors become overactive, they might disrupt the brain circuits controlling movement.^[7]

Ketamine, an anesthetic medication that blocks NMDA receptors, has shown promise in early studies of catatonia treatment. Unlike traditional anesthesia, ketamine at lower doses can help reset brain circuits without putting someone completely to sleep. Some case reports describe rapid improvement in catatonic symptoms after ketamine administration, though larger controlled trials are still needed to confirm its effectiveness and safety.^[7]

Memantine, another medication that affects NMDA receptors, is being explored as a potential treatment. Originally approved for Alzheimer’s disease, memantine works more gently than ketamine, blocking excessive NMDA activity while allowing normal signaling to continue. This might make it suitable for longer-term use in preventing catatonia recurrence, though research remains in early phases.^[13]

These medications represent Phase II research, meaning scientists are testing whether they actually work to treat catatonia and determining the right doses. Early results suggest they might be particularly helpful for people whose catatonia doesn’t respond to benzodiazepines, offering an alternative to ECT. Clinical trials are examining both the immediate effects on acute catatonia and the potential for preventing future episodes.^[7]

Understanding Brain Circuit Disruptions

Recent research has revealed that catatonia involves disruption of a specific neural pathway connecting several brain regions: the basal ganglia, thalamus, and areas of the cortex responsible for planning and executing movements. This circuit normally coordinates smooth, purposeful movements and helps us start and stop actions appropriately. When these connections malfunction, the result can be the frozen immobility or excessive, purposeless movements characteristic of catatonia.^[7]

This understanding has led researchers to investigate treatments that target these specific brain regions. Transcranial magnetic stimulation, a technique that uses magnetic fields to stimulate specific brain areas, is being studied in small trials. Early Phase I studies focus on safety and whether the technique can reach the right brain regions. Phase II studies are beginning to test whether it actually improves catatonic symptoms.^[10]

The connection between catatonia and other movement disorders like Parkinson’s disease has sparked interest in dopamine-affecting medications. Researchers are examining whether medications like levodopa, commonly used for Parkinson’s, might help specific subtypes of catatonia. These studies are still in early phases, primarily conducted in research centers in the United States and Europe.^[13]

Novel Medication Approaches

Clinical researchers are testing combinations of medications that target multiple neurotransmitter systems simultaneously. For example, some trials combine benzodiazepines with dopamine-enhancing drugs or medications that affect other brain chemical systems. The rationale is that different people’s catatonia may involve different neurotransmitter imbalances, so combination therapy might work when single medications fail.^[12]

Studies of thyroid hormone supplementation have shown some promise, particularly for people whose catatonia proves resistant to standard treatments. These Phase II trials typically involve small numbers of patients and focus on measuring changes in catatonia rating scales and overall functioning. The mechanism isn’t fully understood, but thyroid hormones affect brain metabolism and might help restore normal neural circuit function.^[12]

Cyclooxygenase inhibitors, which are anti-inflammatory medications, have shown protective effects in animal studies. Researchers observed that these medications prevented catatonia-like symptoms in rats exposed to certain antipsychotic drugs. Human trials are beginning to explore whether inflammation plays a role in some cases of catatonia and whether anti-inflammatory approaches might help.^[12]

Trial Locations and Patient Eligibility

Most clinical trials for catatonia treatment take place at university medical centers in the United States, Europe, and other developed regions. These trials typically recruit patients who have been diagnosed with catatonia using standardized rating scales like the Bush-Francis Catatonia Rating Scale. Eligibility criteria usually include having catatonia that hasn’t responded adequately to standard benzodiazepine treatment.^[10]

Phase I trials focus primarily on safety and usually involve healthy volunteers or a very small number of patients. Phase II trials expand to include more people with catatonia, testing whether the treatment actually improves symptoms. Phase III trials, when they occur, compare new treatments directly against standard care like lorazepam or ECT to determine whether the new approach offers any advantages.^[5]

People interested in participating in clinical trials for catatonia should discuss options with their psychiatrist or neurologist. Because catatonia can be severe and requires prompt treatment, trial participation usually becomes an option after initial stabilization with standard treatments, or for people experiencing recurring episodes despite ongoing care.^[5]

Most Common Treatment Methods

• Benzodiazepine medications
  • Lorazepam as the first-line treatment, usually given in divided doses throughout the day
  • Clonazepam and midazolam as alternative options when lorazepam is unavailable or ineffective
  • Work by enhancing GABA activity in the brain to calm overactive neural circuits
  • Can be administered orally or intravenously depending on the person’s ability to swallow
  • Response often visible within hours to days of starting treatment
• Electroconvulsive therapy (ECT)
  • Most effective treatment overall, particularly when medications fail
  • Involves controlled electrical currents delivered to the brain under anesthesia
  • Typically given three times per week for several weeks
  • Success rate of 80 to 100 percent for catatonia treatment
  • May require maintenance sessions on an outpatient basis to prevent recurrence
• Alternative pharmacological treatments
  • Zolpidem for cases not responding to standard benzodiazepines
  • Amantadine and bromocriptine to increase dopamine activity
  • Carbamazepine for mood stabilization and neural circuit regulation
  • Dantrolene for malignant catatonia with fever and severe muscle rigidity
• Investigational approaches in clinical trials
  • Ketamine for rapid symptom relief through NMDA receptor blockade
  • Memantine for longer-term prevention of recurrence
  • Transcranial magnetic stimulation targeting specific brain regions
  • Combination medication strategies addressing multiple neurotransmitter systems
  • Anti-inflammatory medications based on emerging theories about inflammation’s role
• Supportive care measures
  • Intravenous fluids and nutrition for people unable to eat or drink
  • Monitoring of vital signs including temperature, heart rate, and blood pressure
  • Physical therapy to restore strength and coordination after immobility
  • Occupational therapy for regaining independence in daily activities
  • One-on-one supervision when needed to prevent injury to self or others